Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Efficacy and Safety of Aracmyn® [Antivenin Latrodectus (Black Widow)Equine Immune F(ab)2], in Patients With Systemic Latrodectism: A Phase II, Multi-center, Randomized, Double-Blind Trial

NCT00247078 is registered in ClinicalTrials.gov with Instituto Bioclon S.A. de C.V. as lead sponsor.

NCT NCT00247078
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00247078 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Efficacy and Safety of Aracmyn® [Antivenin Latrodectus (Black Widow)Equine Immune F(ab)2], in Patients With Systemic Latrodectism: A Phase II, Multi-center, Randomized, Double-Blind Trial
Lead sponsor
Instituto Bioclon S.A. de C.V.
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2005
Completion date
December 31, 2006
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

arachnidism, latrodectism